Clinical and animal studies revealed that IL-13 might be protective in the development of MASH through both the preservation of metabolic functions and Th2-polarized inflammation in the liver and the adipose tissue. The gene discussed is IL13; the disease is metabolic dysfunction-associated steatohepatitis.